Onconetix, Inc. Deferred Income Tax Liabilities, Net
Onconetix, Inc. (ONCO) had Deferred Income Tax Liabilities, Net of $2.87 million as of 2024-09-30, per its 10-Q filed 2024-12-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2025-06-02
- 2024-09-30: Deferred Income Tax Liabilities, Net $2.87M.
- 2024-06-30: Deferred Income Tax Liabilities, Net $2.81M.
- 2024-03-31: Deferred Income Tax Liabilities, Net $2.74M.
- 2023-12-31: Deferred Income Tax Liabilities, Net $3.07M.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2024-09-30 | $2.87M 10-Q · filed 2024-12-10 |
| 2024-06-30 | $2.81M 10-Q · filed 2024-08-29 |
| 2024-03-31 | $2.74M 10-Q · filed 2024-05-20 |
| 2023-12-31 | $3.07M 10-K · filed 2025-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |